Recent advances in the molecular pathology of lung cancer: role of EGFR and KRAS mutation testing in treatment selection
|
|
- Kristian Harrington
- 5 years ago
- Views:
Transcription
1 ASIP 2009 USCAP Companion Meeting Molecular Pathology for the Practicing Pathologist Recent advances in the molecular pathology of lung cancer: role of EGFR and KRAS mutation testing in treatment selection Marc Ladanyi, M.D. Memorial Sloan-Kettering Cancer Center New York, NY Web resources The Sanger Institute (U.K.) maintains the COSMIC database (Catalogue Of Somatic Mutations In Cancer) that includes a listing of all reported EGFR mutations, as well as mutations in KRAS and other kinases: The City of Hope Clinical Molecular Diagnostic Laboratory (Duarte, CA) maintains an EGFR mutation database: Recent reviews and articles Papadopoulos N, Kinzler KW, Vogelstein B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat Biotechnol 2006;24: Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12: Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7: Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25: Pao W, Ladanyi M. EGFR mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 13: , Li AR, Chitale D, Riely GJ, Pao W, Ma Y, Zheng T, Miller VA, Zakowski MF, Kris MG, Ladanyi M. EGFR mutations in lung adenocarcinomas: clinical testing experience and their relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 10: , 2008.
2 Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Venkatraman ES, Ladanyi M, Pao W. Prognostic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thoracic Oncology 3: , Pratilas CA, et al: Genetic predictors of MEK-dependence in non-small cell lung cancer. Cancer Res 68: , Ding L, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: , Riely GJ, Kris MG, Rosenbaum D, Marks J, Li AR, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, Miller VA, Ladanyi M. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14: , Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 21, S16-S22, Riely GJ, Ladanyi M. KRAS Mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn 10: , Garcia J, Riely GJ, Nafa K, Ladanyi M. KRAS mutational testing in the selection of patients for EGFR-targeted therapies. Sem Diagn Pathol 25:288-94, 2008.
3 Recent advances in the molecular pathology of lung cancer: role of EGFR and KRAS mutation testing in treatment selection Marc Ladanyi, M.D. Chief, Molecular Diagnostics Service Memorial Sloan-Kettering Cancer Center New York, NY, USA
4 Targeted therapies of cancer with molecular predictive markers the new paradigm
5 Predictive molecular testing for targeted therapy of lung cancers 1. Testing for EGFR and KRAS mutations in Lung Cancer 2. Beyond EGFR and KRAS
6 EGFR EGFR is a receptor tyrosine kinase of the ErbB family 4 closely related receptors ErbB1 EGFR, HER1 ErbB2 HER2/neu ErbB3 HER3 ErbB4 HER4
7
8 Small molecule EGFR tyrosine kinase inhibitors (TKIs) Erlotinib Tarceva (Genentech) Gefitinib Iressa (Astra-Zeneca) Oral drugs with relatively low toxicity (rash, diarrhea) Pharmacokinetics once-daily dosing Expression of EGFR by IHC in large proportion (50-60%) of lung CA provided initial rationale for trials
9 Dramatic response to gefitinib
10 Histologic features of responders to EGFR inhibitors Responders: typically well to moderately differentiated; peripheral pure BAC or adenocarcinoma with BAC component
11 Histologic features of responders to EGFR inhibitors Responders: typically well to moderately differentiated adenocarcinoma BAC components, papillary components peripheral; TTF1 + often with (non-mucinous) BAC component Non-responders: more often poorly differentiated; more often TTF1-negative pure squamous carcinomas (in contrast to adenosquamous CA) mucinous BAC (assoc with KRAS mutations) Histologic overlap between the 2 populations Among lung adenocarcinomas, negative predictive value of morphologic features insufficient to exclude EGFR mutation testing
12 Discovery of activating mutations in EGFR kinase domain in lung cancers (2004)
13 EGFR Mutations Associated with Sensitivity to EGFR-TKIs EGF ligand binding Tyrosine kinase autophos TM K DFG Y Y Y Y GXGXXG K DFG L L Exon: LREA G719A/C deletion L858R L861Q Mutations described in first reports. Lynch et al 04; Paez et al 04; Pao et al 04
14 EGFR Mutations and EGFR TKI Responses Data cumulated by Sequist et al., JCO March 2007 EGFR mutations: Among responders = ~ 80% Among non-responders = 7% Reasons:? Not all EGFR mutations confer sensitivity,? Other mutations (e.g. PTEN loss, PIK3CA mut, etc..) Responses: Among EGFR-mutant cases = ~ 80% Among EGFR-mutation negative cases = 10% Reasons:? undetected EGFR mutations due to limited extent or poor sensitivity of direct sequencing direct sequencing is likely to miss mutations when the tumor cells make up less than 25% of the sample
15 Association between EGFR mutation and EGFR Amplification Difficult to tease out because of their frequent cooccurrence. Reported ranges vary depending on technique, criteria and interobserver variability Among EGFR mutated cases, ~50% show increased EGFR copy number ~75% of cases with increased EGFR copy number show mutations.
16 A CISH - neg CISH - low CISH - high C EGFR mutation 29/60 EGFR amplification by CISH 20/ B IHC 0 IHC EGFR overexpression by IHC 29/60 IHC 2+ IHC 3+
17 Mutation status may be more rational for treatment selection The response rates to EGFR TKIs are high in the EGFR mutated case regardless of the copy number. The EGFR amplified cases that lack mutations have very low response rates in the order on 1-8%. When both alterations are present, the mutated allele is preferentially amplified suggesting that it is the mutation what drives the selection for copy number gains.
18 Phase II trial of erlotinib in 101 pts with BAC or adenocarcinoma, BAC subtype EGFR Status n Response (%) Median PFS (mo) Mut+/CISH Mut+/CISH < Mut-/CISH Mut-/CISH < Miller VA, et al. Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma BAC Subtype Predict Response to Erlotinib. J Clin Oncol 26:1472-8, 2008.
19 Phase II trial of erlotinib in 101 pts with BAC or adenocarcinoma, BAC subtype Waterfall plot of maximal reduction of indicator lesions Miller VA, et al. Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma BAC Subtype Predict Response to Erlotinib. J Clin Oncol 26:1472-8, 2008.
20 Mutant EGFR is biologically linked to ligand independent activation and increased downstream signaling. EGFR mutations more closely linked to known risk factors and patient profile (female, Asian, non-smoker) than is EGFR amplification.
21 Pts with EGFR Mutations Survive Longer on Gefitinib Prospective studies Han et al, JCO 05 Mitsudomi et al, JCO 05 Taron et al, CCR 05 Tokumo et al, CCR 05 Cortes-Funes et al, Ann Oncol 05
22 Iressa Pan Asian Study (ipass) Patients Chemonaïve Age 18 years Adenocarcinoma histology Never or light exsmokers* Life expectancy 12 weeks PS 0-2 Measurable stage IIIB / IV disease Gefitinib (250 mg / day) 1:1 randomization Carboplatin (AUC 5 or 6) / paclitaxel (200 mg / m 2 ) 3 weekly # Endpoints Primary Progression-free survival (non-inferiority) Secondary Objective response rate Overall survival Quality of life Disease-related symptoms Safety and tolerability Exploratory Biomarkers EGFR mutation EGFR-gene-copy number EGFR protein expression *Never smokers, <100 cigarettes in lifetime; light ex-smokers, stopped 15 years ago and smoked 10 pack years; # limited to a maximum of 6 cycles Carboplatin / paclitaxel was offered to gefitinib patients upon progression PS, performance status; EGFR, epidermal growth factor receptor Tony Mok
23 ipass - Study Details 87 centers in 9 countries in Asia China, Hong Kong, Indonesia, Japan, Malaysia, Philippines, Singapore, Taiwan, Thailand 1217 patients randomized Randomisation period: March 2006 to October 2007 Data cut-off: 14 April PFS events observed in ITT population (78% maturity) Mean time on treatment gefitinib, 6.4 months carboplatin / paclitaxel, 3.4 months (median number of cycles # : 6) Final survival data (944 events) expected mid-2010 Myanmar Hong Kong # limited to a maximum of 6 cycles PFS, progression-free survival; ITT, intent-to-treat Tony Mok
24 Iressa Pan Asian Study (ipass) Overall EGFR mutation positive rate = 59.7% (261 / 437)!! Tony Mok
25 ipass - Comparison of PFS by mutation status within treatment arms Probability of PFS Gefitinib EGFR M+ (n=132) Gefitinib EGFR M- (n=91) Carboplatin / paclitaxel EGFR M+ (n=129) Carboplatin / paclitaxel EGFR M- (n=85) Gefitinib, HR=0.19, 95% CI 0.13, 0.26, p< No. events M+ = 97 (73.5%) No. events M- = 88 (96.7%) Carboplatin / paclitaxel, HR=0.78, 95% CI 0.57, 1.06, p= No. events M+ = 111 (86.0%) No. events M- = 70 (82.4%) Time from randomization (months) M+, mutation positive; M-, mutation negative Tony Mok
26 Dramatic responses to EGFR inhibitor gefitinib, but usually not durable 1 month Durable responses (>3 yrs) in some, but most patients progress after 6-12 months. 1 month
27 Resistance to EGFR-TKIs Primary resistance Tumors that are refractory to EGFR TKIs from the outset Genetic predictors at diagnosis KRAS mutations (common); PTEN loss? EGFR mutations not sensitive to EGFR TKIs (rare, ~2%) ex 20 insertion BRAF mutations (rare, ~3%) In most cases, no good negative predictor Secondary resistance Tumors that are initially sensitive to EGFR TKIs but eventually progress while on therapy Most, if not all, initial responders Genetic finding: second EGFR mutation: T790M (most) MET amplification (some) Second generation EGFR TKIs effective against T790M and ex20 insertions (and mutant HER2)
28 KRAS Mutations: A Negative Predictor for Response to EGFR TKIs in lung cancer Riely GJ, Ladanyi M. KRAS Mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn 10: , BUT, while KRAS mutations are found in about 15-30% of American lung adenocarcinomas, they are found in only <10% of Asian samples
29 Mutations in the EGFR Pathway in lung adenocarcinoma Ligand Ligand-binding domain Mutations in EGFR and KRAS are mutually exclusive. PI3K K K Grb-2 SOS RAS RAF PTEN AKT MEK mtor STAT 3/5 MAPK Survival Proliferation
30 KRAS patient profile compared to EGFR Smoking history more common No association with BAC histology (except mucinous BAC) Less common in Asians than non- Asians
31 Does it matter? EGFR and KRAS mutations: predictors of survival in resected lung adenoca p = EGFR n = 38 KRAS n = 50 Marks et al JTO 08
32 KRAS patient profile compared to EGFR Riely GJ, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14: , 2008.
33 All All Lung Cancers resected at at MSKCC Clinical EGFR/KRAS testing at MSKCC: current flowchart Non-Adenocarcinoma No testing Special request only Adenocarcinoma Reflex testing EGFR mutation testing if negative KRAS mutation testing Adenocarcinoma pts seen by Thoracic Oncologists EGFR initiated late 2004 KRAS initiated late / week ; 750 / year
34 All All Lung Cancers resected at at MSKCC Clinical EGFR/KRAS testing at MSKCC: current flowchart Non-Adenocarcinoma No testing Special request only Adenocarcinoma Reflex testing EGFR mutation testing if negative KRAS mutation testing Adenocarcinoma pts seen by Thoracic Oncologists Feasibility issues Outside pts: in 2007, 700 advanced stage pts through Thoracic Oncology 1/3 come with 15 unstained slides or blocks Operated pts: reflex testing in 1 year period: 500 lung resections 297 adenocas 295 (98%) studied for EGFR/KRAS 58 (20%) EGFR 85 (28%) KRAS
35 All All Lung Cancers resected at at MSKCC Clinical EGFR/KRAS testing at MSKCC: current flowchart Non-Adenocarcinoma No testing Special request only Adenocarcinoma Reflex testing EGFR mutation testing if negative KRAS mutation testing Adenocarcinoma pts seen by Thoracic Oncologists Test ex19 del and L858R only PCR-based mut-specific assays Diagnostic sensitivity: 90% Technical sensitivity: 5-10% Test ex2 / codon 12 & 13 only Direct seq (+/- macrodissection) Diagnostic sensitivity: >95% Technical sensitivity: 25%
36 EGFR ex. 19 deletion assay Lab of Diagnostic Molecular Pathology, MSKCC 9bp deletion - approx. 45% of EGFR mutations - 9, 12, 15, 18, or 24 bp deletions (all preserve reading frame) - most often 15 bp deletion eliminating amino acids ELREA EGFR-Ex19-FWD1 12bp deletion Hotspot for interstitial deletions 15bp deletion EGFR-Ex19-REV1 FAM 18bp deletion
37 EGFR ex. 21 L858R mutation assay Lab of Diagnostic Molecular Pathology, MSKCC - approx. 40% of EGFR mutations - substitution of leucine by arginine at codon 858 (L858R) Undigested sample EGFR-Ex21-FWD1 Sau96I (GGNCC) cctcacagcagggtcttctctgtttcagggcatgaactacttggaggaccgtcgcttggtgcaccgcgacctg G--M--N--Y--L--E--D--R--R--L--V--H--R--D--L- Digested sample No mutation Sau96I (GGNCC) CGGGCC R GCAGCCAGGAACGTACTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAACTGCTG -A--A--R--N--V--L--V--K--T--P--Q--H--V--K--I--T--D--F--G--L--A--K--L--L- EGFR-Ex21-REV1 Digested GGTGCGGAAGAGAAAGAATACCATGCAGAAGGAGGCAAAgtaaggaggtggctttaggtcagccagcattttcctga sample -G--A--E--E--K--E--Y--H--A--E--G--G--K L858R mutation FAM
38 KRAS mutation assay (PCR-sequencing) Lab of Diagnostic Molecular Pathology, MSKCC F R GGT > GCT G12A
39 Limitations of mutation detection by direct sequencing Sequencing will not detect proportions of tumor cells below the sensitivity level (25%). Microdissection routinely used to increase tumor content (eliminate non-neoplastic areas) Blocks or unstained sections for DNA extraction should be from the most cellular areas with >50% tumor cells. Select sections without excessive inflammatory response.
40 L29T: 35G A H358: 34G T H1734: 37G T 100% 100% 25% 25% 100% 25% Sequencing will not reliably detect proportions of tumor cells below 25%. 12.5% 12.5%? 12.5%? 6.25% 6.25% X 6.25% X Forward Reverse Forward
41 Use of EGFR and KRAS mutation status to select EGFR-TKI therapy Scenario EGFR Mutation KRAS Mutation Treatment Gefitinib or Erlotinib Trial of drug? Alternative agents Extremely rare, if real
42 The Lung Adenocarcinoma Oncogenome Unknown EGFR (2004) KRAS (1987) ALK fusions (2007) ERBB2 (2004) BRAF (2002) PIK3CA (2004) Mutually exclusive mutations: EGFR, KRAS, BRAF, ERBB2
43 Mutations in the EGFR Pathway in lung adenocarcinoma Ligand Ligand-binding domain Mutations in EGFR, KRAS, BRAF, and HER2 are mutually exclusive. PI3K K K Grb-2 SOS RAS RAF PTEN AKT MEK mtor STAT 3/5 MAPK Survival Proliferation
44 BRAF MUTATIONS in Lung CA BRAF mutations identified in 2-3 % of lung adenocarcinoma Most common mutation is V600E, Exon 15 predicts resistance to EGFR inhibition predicts benefit from MEK selective inhibition (Pratilas et al., Cancer Res 68: , 2008)
45 Predictive molecular testing for targeted therapy of lung cancers 1. Testing for EGFR and KRAS mutations in Lung Cancer 2. Beyond EGFR and KRAS
46 Predictive Testing for Targeted Therapies: impact on clinical labs New emphasis on mutation detection Methods need to work on DNA extracted from archival pathology paraffin blocks Methods need to detect mutations even when tumor cells are <10% of tumor biopsy sample Increasing need for higher-throughput molecular diagnostic technologies
47 EGFR mutations in lung adenocarcinoma: beyond exon 19 deletions and exon 21 L858R exon 20 insertions major secondary resistance mut. exon 19 deletions Sharma et al. Nature Reviews Cancer 7, (March 2007)
48 A New Way to Look at Lung Cancer KRAS mutated Squamous Large Cell Adenocarcinoma Non-Small Cell Lung Cancer (Classical Morphologic Categories) 180,000 USA cases in 2008 EGFR mutated BRAF mutated PI3KCA mutated HER2 mutated Adenocarcinoma (New Molecular Categories) 121,000 USA cases in 2008 EGFR testing alone is not enough >5 genes x multiple different mutations/gene = lots of assays 1 mutation / assay no longer sustainable for clinical labs
49 Nature Oct 23, 2008
50 Next generation molecular diagnostics: screening for multiple mutations more efficiently What s needed: high throughput / high sensitivity Multiplexing (multiple mutations tested / assay) Automated liquid handling (reduce labor costs) need to detect mutations even when tumor cells are only 5% (or less) of tumor biopsy sample Semi-automated mutation calling would be nice New technology in place at MSKCC since 2006: Sequenom: instrument for highly multiplexed mass spectrometry-based nucleic acid assays
51 Sequenom system Mass spectrometry-based nucleic acid assays Assay Design Genotyping Assay Design 3 primers specific to each SNP or mutation: 2 PCR Primers 1 Extend primer 3 or 5 adjacent to the SNP point mutation detected by different mass of single base extension product
52 Sequenom assays for lung kinase mutations H358 cell line: KRAS 34 G>T Mutation 1 Mut : 1 WT WT Peak G measure presence of >20 mutations per assay MUT Peak T automated detection of mutations; followed by manual review sensitivity: 5-10% (if manual review)
53 Clinical Genes in Sequenom Panel example: KRAS & EGFR Total # of mutations in COSMIC % of mutations for gene coding sequence mutation amino acid change Cases Gene KRAS c.34g>t p.g12c KRAS c.34g>c p.g12r KRAS c.34g>a p.g12s KRAS c.35g>c p.g12a KRAS c.35g>a p.g12d KRAS c.35g>t p.g12v KRAS c.37g>t p.g13c KRAS c.37g>c p.g13r KRAS c.37g>a p.g13s KRAS c.38g>c p.g13a KRAS c.38g>a p.g13d KRAS c.38g>t p.g13v KRAS c.181c>g p.q61e KRAS c.181c>a p.q61k KRAS c.182a>t p.q61l KRAS c.182a>c p.q61p KRAS c.182a>g p.q61r KRAS c.183a>c p.q61h KRAS c.183a>t p.q61h KRAS c.436g>c p.a146p KRAS c.436g>a p.a146t Total # of mutations in COSMIC % of mutations for gene coding sequence mutation amino acid change Cases Gene EGFR c.2155g>t p.g719c EGFR c.2155g>a p.g719s EGFR c.2156g>c p.g719a EGFR c.2156g>a p.g719d 2791 >1000 >36% EGFR c.2235 deletion EGFR c.2236 deletion EGFR c.2237 deletion EGFR c.2238 deletion EGFR c.2239 deletion EGFR c.2240 deletion EGFR c.2241 deletion EGFR c.2281g>t p.d761y EGFR c.2303g>t p.s768i EGFR c.2369c>t p.t790m ? EGFR c.2560a>g p.t854a EGFR c.2572c>a p.l858m EGFR c.2573t>g p.l858r EGFR c.2582t>a p.l861q EGFR c.2582t>g p.l861q
54 Research Genes in Sequenom Panel example: BRAF & PIK3CA Total # of mutations in COSMIC % of mutations for gene coding sequence mutation amino acid change Cases Gene BRAF c.1406g>c p.g469a BRAF c.1406g>a p.g469e BRAF c.1406g>t p.g469v BRAF c.1781a>g p.d594g BRAF c.1781a>t p.d594v BRAF c.1798g>a p.v600m BRAF c.1799t>c p.v600a BRAF c.1799t>a p.v600e BRAF c.1799t>g p.v600g Total # of mutations in COSMIC Cases % of mutations for gene Gene coding sequence mutation PIK3CA c.263g>a p.r88q amino acid change PIK3CA c.1258t>c p.c420r PIK3CA c.1624g>a p.e542k PIK3CA c.1624g>c p.e542q PIK3CA c.1634a>c p.e545a PIK3CA c.1634a>g p.e545g PIK3CA c.1635g>t p.e545d PIK3CA c.1633g>a p.e545k PIK3CA c.3129g>t p.m1043i PIK3CA c.3140a>t p.h1047l PIK3CA c.3140a>g p.h1047r PIK3CA c.3139c>t p.h1047y
55 Clinical / Research tumor mutation profiling Present platform: Sequenom mass-spec genotyping Great for recurrent point mutations in oncogenes Sensitivity: 5-10% Good for poor quality DNA Applicable to known gene fusions at cdna level only Poor for insertions, deletions Poor for tumor suppressor genes (P53, PTEN, NF1, STK11) because point mutations less recurrent, more scattered Not good for previously unknown mutations
56 Predictive Testing for Targeted Therapies: impact on clinical trials Phase 1: safety and dosage Phase 2: efficacy and safety Phase 3: randomized controlled study
57 Predictive Testing for Targeted Therapies: impact on practice Nature Biotechnology, August 2006
58 Predictive molecular testing for targeted therapy of lung cancers 1. Testing for EGFR and KRAS mutations in Lung Cancer 2. Beyond EGFR and KRAS
59 Acknowledgements Some slides graciously provided by: William Pao, MD PhD Maria Arcila, MD
Changing demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationTHE FUTURE OF PAP SMEAR SCREENING IN THE ERA OF MOLECULAR DIAGNOSTICS AND VACCINES MARK H STOLER, MD ASIP COMPANION MEETING USACP 2009
Stoler, MH THE FUTURE OF PAP SMEAR SCREENING IN THE ERA OF MOLECULAR DIAGNOSTICS AND VACCINES MARK H STOLER, MD ASIP COMPANION MEETING USACP 2009 TAKE HOME BULLET POINTS: 1. MORPHOLOGY BASED SCREENING
More informationTHE FUTURE OF PAP SMEAR SCREENING IN THE ERA OF MOLECULAR DIAGNOSTICS AND VACCINES MARK H STOLER, MD ASIP COMPANION MEETING USACP 2009
Stoler, MH THE FUTURE OF PAP SMEAR SCREENING IN THE ERA OF MOLECULAR DIAGNOSTICS AND VACCINES MARK H STOLER, MD ASIP COMPANION MEETING USACP 2009 TAKE HOME BULLET POINTS: 1. MORPHOLOGY BASED SCREENING
More informationThe Personalized Cancer Medicine Initiative at Vanderbilt
The Personalized Cancer Medicine Initiative at Vanderbilt October 26, 2009 William Pao, MD, PhD Assistant Director, Personalized Cancer Medicine Vanderbilt-Ingram Cancer Center Cancer in the United States,
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationEGFR, Lung Cancer and Cytology. Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan.
EGFR, Lung Cancer and Cytology Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan. It is histopathologically divided into two major sub-groups: Small
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationHOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
More informationDisclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationWhole Exome Sequenced Characteristics
Supplementary Tables Supplementary Table 1: Patient characteristics of 45 whole exome sequenced HNSCC tumors Whole Exome Sequenced Characteristics Tumors (n=45) Age, years Median (range) 61.0 (19-90) Sex,
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationand management of lung cancer Maureen F. Zakowski, M.D. Memorial Sloan-Kettering Cancer Center
The new role of cytology in the diagnosis and management of lung cancer Maureen F. Zakowski, M.D. Memorial Sloan-Kettering Cancer Center Outline Role of cytology in the diagnosis of lung cancer Non-small
More informationFrequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationJuly 2015 Assay ID Assay Name Gene COSMIC ID Amino acid change Nucleotide change Wild type allele (VIC label) Mutant allele (FAM label)
July 2015 Assay ID Assay Name Gene COSMIC ID Amino acid change Nucleotide change Wild type allele (VIC label) Mutant allele (FAM label) p AHLJ090 AKT1_33765 AKT1 33765 p.e17k c.49g>a C T 2 AHBKFRM BRAF_473
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationLung adenocarcinoma: guiding EGFR-targeted therapy and beyond
& 2008 USCAP, Inc All rights reserved 0893-3952/08 $30.00 www.modernpathology.org : guiding EGFR-targeted therapy and beyond Marc Ladanyi and William Pao Departments of Pathology and Medicine, and Human
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationThe discovery of targetable driver mutations in a subset of
Original Article Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers Anya M. Litvak, MD,* Paul K. Paik, MD,* Kaitlin M. Woo, MS, Camelia S. Sima, MD, Matthew D. Hellmann, MD,*
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationMolecular Diagnostics in Lung Cancer
Molecular Diagnostics in Lung Cancer Mutations in lung carcinomas and their impact on diagnosis and treatment With special thanks to: Barbara Chaitin, MD Medical Director, Esoteric Services AmeriPath Orlando,
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationBalazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center
Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Eli-Lilly Pfizer Astellas Daiichi-Sankyo Oncothyreon Astex Astra-Zeneca Bristol-Myers-Squibb Novartis Roche Boehringer-Ingelheim
More informationAdenocarcinoma of the lung is the leading cause of cancerrelated
ORIGINAL ARTICLE Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma Jenifer L. Marks, MD,* Stephen Broderick, MD, Qin Zhou, MA, Dhananjay Chitale, MD, Allan
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationBalazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center
Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Eli-Lilly Pfizer Astellas Daiichi-Sankyo Oncothyreon Astex Astra-Zeneca Bristol-Myers-Squibb Novartis Roche Boehringer-Ingelheim
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationGTS. Earn CME credits at
Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center Sandra P. D Angelo, MD, Bernard Park,
More informationTargeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations
Review Article Page 1 of 5 Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations Gérard A. Milano Oncopharmacology Unit, EA 3836 UNS, Centre Antoine Lacassagne,
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationALK Fusion Oncogenes in Lung Adenocarcinoma
ALK Fusion Oncogenes in Lung Adenocarcinoma Vincent A Miller, MD Associate Attending Physician, Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center New York, New York The identification of
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationPage: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
More informationSupplementary Table 1. PIK3CA mutation in colorectal cancer
Liao X et al. PIK3CA Mutation in Colorectal Cancer. Page 1 Supplementary Table 1. PIK3CA mutation in colorectal cancer Exon Domain Nucleotide change* Amino acid change* cases 9 Helical c.1621t>a p.e541t
More informationRole of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
More informationThe Role of Pathology/Molecular Diagnostic in Personalized Medicine
The Role of Pathology/Molecular Diagnostic in Personalized Medicine Ignacio I. Wistuba, M.D. Jay and Lori Eissenberg Professor in Lung Cancer Director of the Thoracic Molecular Pathology Lab Departments
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More informationNon Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק
Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק 26.06.09 Lecture outlines WHO histological classification Macro/Micro assessment Early diagnosis Minimal pathology Main subtypes SCC, AdCa, LCLC
More informationPIK3CA mutations are found in approximately 7% of
Original Article Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas Juliana Eng, MD,*
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationSUBJECT: GENOTYPING - EPIDERMAL GROWTH
MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationMICROSCOPY PREDICTIVE PROFILING
Immunomodulatory therapy in NSCLC: a year into clinical practice Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor to and speaker
More informationKRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Open access, freely available online KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib PLoS MEDICINE William Pao 1,2*, Theresa Y. Wang 1, Gregory J. Riely 2, Vincent
More informationLihong Ma 1 *, Zhengbo Song 2 *, Yong Song 1, Yiping Zhang 2. Original Article
Original Article MET overexpression coexisting with epidermal growth factor receptor mutation influence clinical efficacy of EGFR-tyrosine kinase inhibitors in lung adenocarcinoma patients Lihong Ma 1
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More informationPersonalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader
Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Agenda PHC Approach Provides Better Patient Outcome FMI offers Comprehensive Genomic Profiling,
More informationEGFR. Pathway and biomarkers. Alex Soltermann
EGFR Pathway and biomarkers Alex Soltermann EGFR = HER1 signaling pathway EGFR Cheng Mod Pathol 2012 Chromosome 7p11.2, spans 200kb, 28 exons, 464 aa, 170 kda protein 2 Signal transduction pathways controlled
More informationPersonalized Healthcare Update
Dr. Kai - Oliver Wesche Market Development Manager, Personalized Healthcare QIAGEN Personalized Healthcare Update Pioneering Personalized Medicine through Partnering TOMTOVOK BKM120 Zelboraf QIAGEN partners:
More informationMolecular Diagnosis of Lung Cancer
Molecular Diagnosis of Lung Cancer Lucian R. Chirieac, M.D. Assistant Professor of Pathology Harvard Medical School Staff Pathologist, Department of Pathology Brigham and Women's Hospital 75 Francis Street
More informationMolecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory
2.04.45 Molecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date November 26, 2014 Original Policy Date November
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationTreatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
More informationTest Category: Prognostic and Predictive. Clinical Scenario
Use of Epidermal Growth Factor Receptor (EGFR) Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) to Determine Erlotinib Use as First-line Therapy Test Category: Prognostic
More informationLiquid biopsy in lung cancer: The EGFR paradigm
Liquid biopsy in lung cancer: The EGFR paradigm Lynette M. Sholl, M.D. Brigham and Women s Hospital Dana Farber Cancer Institute Department of Pathology Boston, MA Disclosure of Relevant Financial Relationships
More information1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
More informationLung cancer is the leading cause of cancer-related
Original Articles Correlation of Mutation Status With Predominant Histologic Subtype of Adenocarcinoma According to the New Lung Adenocarcinoma Classification of the International Association for the Study
More informationPRACTICE GUIDELINE SERIES
ELLIS et al. PRACTICE GUIDELINE SERIES The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent nonsmall-cell lung cancer: a Canadian
More informationThe Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer
The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer Nathan A. Pennell, M.D., Ph.D. Assistant Professor Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute www.cancergrace.org
More informationThe Journal of International Medical Research 2011; 39:
The Journal of International Medical Research 2011; 39: 1392 1401 Serum Detection of Epidermal Growth Factor Receptor Gene Mutations Using Mutant-enriched Sequencing in Chinese Patients with Advanced Non-small
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationEGFR ctdna Testing. Andrew Wallace 21/09/2015 Genomic Diagnostics Laboratory St. Mary s Hospital, Manchester
EGFR ctdna Testing Andrew Wallace 21/09/2015 Genomic Diagnostics Laboratory St. Mary s Hospital, Manchester ctdna & EGFR Testing in NSCLC EGFR ctdna testing Non-invasive - patients too sick/biopsy or cytology
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More information8/22/2016. Major risk factors for the development of lung cancer are: Outline
Carcinomas of the Lung: Changes in Staging, Adenocarcinoma Classification and Genetics Grace Y. Lin, M.D., Ph.D. Outline Background Staging of Lung Cancer: Review of the 2010 7 th Edition of the AJCC Cancer
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationThe ABCs of BAC: Bronchioloalveolar Carcinoma
The ABCs of BAC: Bronchioloalveolar Carcinoma Howard (Jack) West, MD Medical Oncologist Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA March, 2009 President & CEO GRACE
More informationThe Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
More informationIs there a role for EGFR Tyrosine Kinase Inhibitors in recurrent glioblastoma?
Is there a role for EGFR Tyrosine Kinase Inhibitors in recurrent glioblastoma? Juan M Sepúlveda Sánchez Neurooncology Unit Hospital Universitario 12 de Octubre. Madrid Topics 1.-EGFR pathway as a potential
More informationMay 9, Dr. James Almas Medical Director MolDX 17 Technology Circle AG-315 Columbia, SC Dear Dr. Almas:
May 9, 2018 Dr. James Almas Medical Director MolDX 17 Technology Circle AG-315 Columbia, SC 29202 Dear Dr. Almas: On behalf of LUNGevity Foundation, the nation s preeminent lung cancer nonprofit that funds
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More information1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
More informationSupplementary Table 2. Identified causative mutations and/or mutation candidates.
Supplementary Table 2. Identified causative mutations and/or mutation candidates. Nonsense mutations base change aa change Average depth Result of next generation in 432 patient Hereditary form of the
More information4/24/2013. Neal I. Lindeman, MD. Molecular Testing Guideline Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
Molecular Testing Guideline Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Philip T. Cagle, MD, Marc Ladanyi, MD, Neal I. Lindeman, MD April 24, 2013 cap.org v. # Guideline
More informationAn ongoing research and multiple clinical
TARGETED THERAPIES IN LUNG CANCER Lucian R. Chirieac, MD a, *, Sanja Dacic, MD, PhD b KEYWORDS Lung cancer Adenocarcinoma Squamous Tyrosine kinase inhibitors Molecular pathogenesis ABSTRACT An ongoing
More informationNovel treatments for SCC Andrés Felipe Cardona, MD MS PhD.
Novel treatments for SCC Andrés Felipe Cardona, MD MS PhD. Clinical and Transla,onal Oncology Group Ins,tute of Oncology, Fundación Santa fe de Bogotá Clinical Epidemiology Cochrane Colombian Branch /
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Page 1 of 52 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Analysis for Targeted
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More informationMolecular Pathology and Lung Cancer. A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA
Molecular Pathology and Lung Cancer A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA aiafrate@partners.org Disclosures Preliminary patent application NGS AMP Fusion
More informationMOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE
25 th IAP-Arab Division Conference 07-09 November 2013, Amman, Jordan MOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE Fouad Al Dayel, MD, FRCPA, FRCPath Professor and Chairman Department
More informationThe Human Epidermal growth factor Receptor (HER) family: structure and function
Chapter 2 The Human Epidermal growth factor Receptor (HER) family: structure and function Epidermal growth factor receptor (EGFR) belongs to a family of four different receptors, including EGFR (ErbB-1;
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationPersonalized Genetics
Personalized Genetics Understanding Your Genetic Test Results Tracey Evans, MD September 29, 2017 Genetics 101 Punnett Square Genetic Pedigree 2 Genetics 101 Punnett Square Genetic Pedigree 3 It s not
More informationAdvances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
More informationKEY FINDINGS 1. Potential Clinical Benefit in Non-Small Cell Lung Cancer with Gefitinib, Erlotinib, Afatinib due to EGFR E746_A750del. 2. Potential Cl
PATIENT INFO SAMPLE REFERING PHYSICIAN COPY TO (if different from ordering) Name: John Smith Date Collected: 10/23/2016 Name: Oncologist, M.D. Name: Pathologist, M.D. DOB: 04/22/1937 Date Received: 10/24/2016
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationMolecular Diagnostics Overview JAN A. NOWAK, PHD, MD PATHOLOGY AND LABORATORY MEDICINE MOLECULAR DIAGNOSTICS LABORATORY FEBRUARY 15, 2018
Molecular Diagnostics Overview JAN A. NOWAK, PHD, MD PATHOLOGY AND LABORATORY MEDICINE MOLECULAR DIAGNOSTICS LABORATORY FEBRUARY 15, 2018 Some Key Points Molecular Testing has applications in every section
More informationRob Ross, MD. Infinity Pharmaceuticals March 9 th, 2011
Heat Shock Protein 90 (Hsp90) Inhibition as a Potential Novel Approach to the Treatment of Patients with ALK Mutated Non-small Cell Lung Cancer (NSCLC) Rob Ross, MD Infinity Pharmaceuticals March 9 th,
More informationBiomarkers in oncology drug development
Biomarkers in oncology drug development Andrew Stone Stone Biostatistics Ltd EFSPI Biomarkers and Subgroups June 2016 E: andrew@stonebiostatistics.com T: +44 (0) 7919 211836 W: stonebiostatistics.com available
More informationKRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS
UNIVERSITÀ DEGLI STUDI DI PALERMO Scuola di Specializzazione in Biochimica Clinica Direttore Prof. Marcello Ciaccio KRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS Loredana Bruno KRAS gene Proto-oncogene
More informationCAP Laboratory Improvement Programs. Worldwide Frequency of Commonly Detected EGFR Mutations
CAP Laboratory Improvement Programs Worldwide Frequency of Commonly Detected EGFR Mutations Rondell P. Graham, MBBS; Amanda L. Treece, MD; Neal I. Lindeman, MD; Patricia Vasalos, BS; Mu Shan, BS; Lawrence
More informationSelecting the right patients for the right trials.
Selecting the right patients for the right trials. Paul Waring Professor of Pathology University of Melbourne June 21, 2011 RCPA Genetics short course Drug development challenges. Current model of drug
More information